當前位置:BPS Bioscience Inc.>>Immunotherapy Cell Lines>> 78757CD8+ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line
This cell line was generated from TCR Knockout NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) by exogeneous overexpression of human CD8 (NM_001768.6) using lentiviral transduction (CD8a Lentivirus, BPS Bioscience #78648). To achieve knockout of TCR (T Cell Receptor), the TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from recombinant Jurkat cells stably expressing the firefly luciferase gene under the control of NFAT response elements.
TCRα/β knockout in the TCR Knockout NFAT-Luciferase Reporter Jurkat cells was confirmed by genomic sequencing and by flow cytometry and expression of CD8 was confirmed by flow cytometry. The cell line has been functionally validated and does not respond to anti-CD3 agonist antibodies, as opposed to parental NFAT-Luciferase Reporter Jurkat cells (BPS Bioscience #60621).
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,化工儀器網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。